港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维昇药业-B

46.220

0.000

成交量：1,000.00

成交额：4.62万

市值：52.69亿

市盈率：-23.75

高：46.220

开：46.220

低：46.220

收：46.220

52周最高：69.150

52周最低：39.250

股本：1.14亿

香港流通股本：1.14亿

量比：0.09

换手率：0.00%

股息：- -

股息率：- -

每股收益(LYR):-1.946

净资产收益率：-57.66%

总资产收益率：-29.52%

市净率：20.01

市盈率(LYR):-23.75

市销率: 1738.59

数据加载中...

总览公司新闻公告

Ascendis 上半年产品收入大涨 155%，维升药业拥有国内权益

Insight数据库

维升药业-B07月31日遭主力抛售37.4万元

维升药业－Ｂ(02561)股价上升5.07%，现价港币$52.85

阿斯达克财经

用于成人！长效生长激素获 FDA 批准上市，维升药业拥有国内权益

Insight数据库

维升药业-B07月28日主力净流入99.8万元散户资金抛售

维升药业-B07月22日主力净流出32.9万元散户资金买入

维升药业-B(02561)携手安科生物加速长效生长激素中国商业化进程

“IPO盛宴”强势回归

艾美达医药咨询

生物药产业合力突围：一款新型长效激素的本土化落地样本

维升药业-B07月04日主力净流出32.2万元散户资金买入

维升药业红筹架构及高管员工持股分析

维升药业-B(02561)：选举付山继任董事会主席

维升药业-B06月27日主力净流出29.5万元散户资金买入

25家中国内分泌与代谢领域创新药公司获融资！

维升药业-B06月19日主力净流出27.7万元散户资金买入

维升药业-B06月18日主力净流入28.1万元散户资金抛售

维升药业-B06月17日主力净流出73.9万元散户资金买入

港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实那韦培肽新药申请获FDA受理

医药生物IPO“港漂”热潮：三大热门创新药成焦点，恒瑞医药4个月便实现A+H

维升药业的独立性与生长激素困局

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02561/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02561","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维昇药业-B","latestPrice":46.22,"timestamp":1756178116199,"preClose":46.22,"halted":0,"volume":1000,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"交易中","change":0,"latestTime":"08-26 11:24:09","open":46.22,"high":46.22,"low":46.22,"amount":46220,"amplitude":0,"askPrice":46.42,"askSize":600,"bidPrice":46.22,"bidSize":2100,"shortable":0,"etf":0,"ttmEps":-1.946273,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1756180800000},"marketStatusCode":2,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":46.22,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":0.086957,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","floatShares":113999999,"roa":"-29.52%","roe":"-57.66%","lyrEps":-1.946273,"volumeRatio":0.086957,"shares":113999999,"dividePrice":0,"high":46.22,"amplitude":0,"preClose":46.22,"low":46.22,"week52Low":39.25,"pbRate":"20.01","psRate":"1738.59","week52High":69.15,"institutionHeld":0,"latestPrice":46.22,"committee":0.555556,"eps":-1.946273,"divideRate":0,"volume":1000,"delay":0,"ttmEps":-1.946273,"open":46.22,"prevYearClose":68.8,"prevWeekClose":46.48,"prevMonthClose":49,"prevQuarterClose":45.3,"fiveDayClose":47.02,"twentyDayClose":50.3,"sixtyDayClose":44.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02561\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02561\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1746460800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02561\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02561","date":"2025-08-25","current":-26.450062,"percent":0.737374,"low":-30.760225,"twenty":-28.117985,"median":-27.175977,"eighty":-26.02136,"high":-17.514985,"avg":-26.732773,"sd":2.485685,"marketCap":5265699654},"quantilePoints":[{"date":"2025-04-03","current":-21.475965,"twenty":-22.637245,"median":-22.569747,"eighty":-22.098421,"marketCap":5724824916},{"date":"2025-04-11","current":-18.134639,"twenty":-22.558476,"median":-18.349759,"eighty":-18.045823,"marketCap":4802017317},{"date":"2025-04-17","current":-25.787715,"twenty":-25.955056,"median":-22.513392,"eighty":-18.141011,"marketCap":4682394110},{"date":"2025-04-25","current":-29.965674,"twenty":-27.695216,"median":-22.653961,"eighty":-18.190408,"marketCap":5445704099},{"date":"2025-05-02","current":-28.244363,"twenty":-27.861811,"median":-26.066617,"eighty":-18.349759,"marketCap":5143797909},{"date":"2025-05-09","current":-27.581562,"twenty":-28.248468,"median":-27.028836,"eighty":-20.850724,"marketCap":5058352761},{"date":"2025-05-16","current":-27.481285,"twenty":-28.307048,"median":-27.470681,"eighty":-22.305907,"marketCap":5081138134},{"date":"2025-05-23","current":-29.180898,"twenty":-28.483617,"median":-27.481285,"eighty":-22.603559,"marketCap":5411526040},{"date":"2025-05-30","current":-27.585218,"twenty":-28.483617,"median":-27.495492,"eighty":-22.648389,"marketCap":5138101566},{"date":"2025-06-06","current":-26.147365,"twenty":-28.307048,"median":-27.481285,"eighty":-24.987287,"marketCap":5212154028},{"date":"2025-06-13","current":-28.707887,"twenty":-28.307048,"median":-27.486097,"eighty":-25.744296,"marketCap":5724824916},{"date":"2025-06-20","current":-27.87701,"twenty":-28.483617,"median":-27.500076,"eighty":-26.010837,"marketCap":5548238276},{"date":"2025-06-27","current":-26.600431,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"marketCap":5308991862},{"date":"2025-07-04","current":-25.999842,"twenty":-28.345085,"median":-27.470681,"eighty":-26.039907,"marketCap":5189368655},{"date":"2025-07-11","current":-25.483255,"twenty":-28.252573,"median":-27.442177,"eighty":-25.700877,"marketCap":5081138134},{"date":"2025-07-18","current":-27.275886,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"marketCap":5434311412},{"date":"2025-07-25","current":-27.917728,"twenty":-28.10544,"median":-27.177054,"eighty":-25.808828,"marketCap":5582416336},{"date":"2025-08-01","current":-26.858726,"twenty":-28.252573,"median":-27.236899,"eighty":-25.835301,"marketCap":5337473578},{"date":"2025-08-08","current":-26.45431,"twenty":-28.168194,"median":-27.174901,"eighty":-25.937332,"marketCap":5270256728},{"date":"2025-08-15","current":-27.513449,"twenty":-28.142473,"median":-27.236899,"eighty":-26.012565,"marketCap":5473046546},{"date":"2025-08-22","current":-26.703746,"twenty":-28.118557,"median":-27.177054,"eighty":-26.021282,"marketCap":5295320638},{"date":"2025-08-25","current":-26.450062,"twenty":-28.117985,"median":-27.175977,"eighty":-26.02136,"marketCap":5265699654}],"updateTime":1756178647926},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02561\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2557517316","title":"Ascendis 上半年产品收入大涨 155%，维升药业拥有国内权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2557517316","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557517316?lang=zh_cn&edition=fundamental","pubTime":"2025-08-08 12:31","pubTimestamp":1754627499,"startTime":"0","endTime":"0","summary":"当地时间 8 月 7 日，维升药业合作伙伴 Ascendis Pharma 发布了 2025 年第二季度和上半年业绩报告。第二季度，该公司营收为 1.58 亿欧元，同比大涨 339%；上半年总营收为 2.59 亿欧元，同比增长 96%。两款商业化产品上半年总计创收 2.5 亿欧元，同比大涨 155%。维升药业拥有帕罗培特立帕肽、隆培生长激素、那韦培肽的大中华区权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808123424a47c5cb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808123424a47c5cb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":1},{"id":"2555884192","title":"维升药业-B07月31日遭主力抛售37.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555884192","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555884192?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 16:15","pubTimestamp":1753949747,"startTime":"0","endTime":"0","summary":"07月31日, 维升药业-B股价跌5.31%，报收49.00元，成交金额454.0万元，换手率0.08%，振幅5.41%，量比1.12。维升药业-B今日主力资金净流出37.4万元，上一交易日主力净流出39.0万元。该股近5个交易日上涨2.52%，主力资金累计净流入23.4万元；近20日主力资金累计净流入191.4万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731170829a46d36a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731170829a46d36a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2555994950","title":"维升药业－Ｂ(02561)股价上升5.07%，现价港币$52.85","url":"https://stock-news.laohu8.com/highlight/detail?id=2555994950","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555994950?lang=zh_cn&edition=fundamental","pubTime":"2025-07-30 11:25","pubTimestamp":1753845900,"startTime":"0","endTime":"0","summary":"[上升股]维升药业－Ｂ(02561) 股价在上午11:25比前收市价上升5.07%，现股价为港币$52.85。至目前为止，今日最高价为$52.85，而最低价为$50.3。总成交量为7.03万股，总成交金额为港币$365.179万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2507301172/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2555609141","title":"用于成人！长效生长激素获 FDA 批准上市，维升药业拥有国内权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2555609141","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555609141?lang=zh_cn&edition=fundamental","pubTime":"2025-07-30 10:36","pubTimestamp":1753842978,"startTime":"0","endTime":"0","summary":"此前该药已获得 FDA 批准用于治疗儿童 GHD 患者。此次获批的成人 GHD 适应症主要基于 foresiGHt 试验的结果，该试验旨在对比每周一次 TransCon hGH 疗法与每周一次安慰剂及每日一次阳性对照药物在成人 GHD 患者中的有效性与安全性。TransCon hGH 已以商品名 Skytrofa 获美国 FDA 与欧盟 EMA 批准，是欧美首个每周一次给药的长效生长激素，用于治疗儿童及青少年 GHD。2024 年 8 月，中国 NMPA 受理其儿童 GHD 适应症上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730110328a46aaebe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730110328a46aaebe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2554776887","title":"维升药业-B07月28日主力净流入99.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2554776887","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554776887?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 16:15","pubTimestamp":1753690543,"startTime":"0","endTime":"0","summary":"07月28日, 维升药业-B股价涨4.39%，报收51.15元，成交金额616.9万元，换手率0.11%，振幅4.90%，量比0.86。维升药业-B今日主力资金净流入99.8万元，上一交易日主力净流出0万元。该股近5个交易日上涨7.57%，主力资金累计净流入104.0万元；近20日主力资金累计净流入221.5万元，其中净流入天数为3日。该股主力净额占比0.02%，港股市场排名273/2673。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728165529a6c5a266&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728165529a6c5a266&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2553372002","title":"维升药业-B07月22日主力净流出32.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2553372002","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553372002?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 16:15","pubTimestamp":1753172143,"startTime":"0","endTime":"0","summary":"07月22日, 维升药业-B股价跌1.58%，报收46.80元，成交金额343.3万元，换手率0.06%，振幅3.79%，量比0.55。维升药业-B今日主力资金净流出32.9万元，上一交易日主力净流入196万元。该股近5个交易日上涨2.74%，主力资金累计净流入163.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入80.6万元，其中净流入天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722170216a45be5f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722170216a45be5f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2551137423","title":"维升药业-B(02561)携手安科生物 加速长效生长激素中国商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2551137423","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551137423?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 10:19","pubTimestamp":1752545983,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B7月14日宣布与安科生物签订战略合作框架协议。在合作期限内，维升药业授权安科生物在中国境内特定区域内排他性独家推广隆培促生长素产品。维升药业与安科生物成功牵手，双方围绕隆培促生长素展开的业务也有望完善安科生物在生长激素方面的布局，实现全剂型覆盖，凭借维升药业创新助力冲击中国市场。该产品目前已在美国及欧洲获批上市，预计2025年内在中国获批，计划在2028年将实现本地化商业生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK1161","BK0060","02561","BK0042","300009","BK0239"],"gpt_icon":0},{"id":"2550683564","title":"“IPO盛宴”强势回归","url":"https://stock-news.laohu8.com/highlight/detail?id=2550683564","media":"艾美达医药咨询","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550683564?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 15:00","pubTimestamp":1752044427,"startTime":"0","endTime":"0","summary":"2025年7月1日，上交所官网显示，武汉禾元生物科技股份有限公司科创板IPO成功通过上交所上市审核委员会审议，成为科创板第五套上市标准重启后首家过会的IPO企业。2025年的A股生物医药IPO市场呈现出积极且结构化的新格局。亦诺微医药、微脉、百力司康等数十家医健企业已向港交所递交上市申请，排队等候上市，场面火爆，预示着下半年IPO热潮将持续。此外，多个IPO项目获得投资者热烈追捧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709150735a69ec54e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709150735a69ec54e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","LU1064131003.USD","LU1997245177.USD","BK0012","600276","159982","BK0239","LU1655091616.SGD","BK0196","BK0028","02561","01877","LU1064130708.USD","LU0405327148.USD","LU2488822045.USD","02617","LU1997244956.HKD","LU2148510915.USD","BK0183","LU1969619763.USD","LU0405327494.USD","LU2495084118.USD","LU1997245094.SGD","BK0060","02592","LU2328871848.SGD","LU1328615791.USD","BK0188"],"gpt_icon":0},{"id":"2548513398","title":"生物药产业合力突围：一款新型长效激素的本土化落地样本","url":"https://stock-news.laohu8.com/highlight/detail?id=2548513398","media":"E药经理人","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548513398?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 18:28","pubTimestamp":1751624921,"startTime":"0","endTime":"0","summary":"在生物药管线冲刺迈入“兑现期”前，如何将高技术壁垒的创新药物真正推向商业化，成为Biotech绕不开的现实大考。但当一部分Biotech挺进临床三期，站到商业化门槛时，一个现实的问题横亘在眼前：如何将创新项目合规、高效、高质量地推向规模化生产，完成从概念验证到商业化落地的完美闭环。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704183403a436c685&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704183403a436c685&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","LU0572944931.SGD","LU0327786744.USD","BK1610","LU0516422366.SGD","LU2039709279.SGD","LU0348825331.USD","LU0181495838.USD","LU0516422440.USD","LU0516423091.SGD","LU0456846285.SGD","LU0979878070.USD","SG9999002562.SGD","LU0417516902.SGD","LU0456827905.SGD","LU0051755006.USD","LU0043850808.USD","LU0348735423.USD","LU1242518857.USD","02269","BK1576","LU0052750758.USD","BK1521","LU1688375341.USD","BK1589","SG9999002463.SGD","LU0359202008.SGD","LU0588546209.SGD","LU0819121731.USD","LU1794554557.SGD","IE00B0JY6N72.USD","LU0417516738.SGD","LU0823426308.USD","LU0359201612.USD","WXIBF","LU0140636845.USD","LU0823426480.USD","LU0039217434.USD","LU0856984785.SGD","LU0326950275.SGD","LU1242518931.SGD","LU1720050803.USD","LU0708995583.HKD","LU1880383366.USD","LU0516423174.USD","02561","LU0320764599.SGD","LU0516422952.EUR","LU0307460666.USD"],"gpt_icon":0},{"id":"2548361593","title":"维升药业-B07月04日主力净流出32.2万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2548361593","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548361593?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 16:15","pubTimestamp":1751616942,"startTime":"0","endTime":"0","summary":"07月04日, 维升药业-B股价跌1.19%，报收45.55元，成交金额132.1万元，换手率0.03%，振幅2.17%，量比0.85。维升药业-B今日主力资金净流出32.2万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.21%，主力资金累计净流出108.0万元；近20日主力资金累计净流入242.7万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704170151a43691a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704170151a43691a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2548265148","title":"维升药业红筹架构及高管员工持股分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2548265148","media":"恒杉咨询","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548265148?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 15:14","pubTimestamp":1751440481,"startTime":"0","endTime":"0","summary":"而维升药业目前产品多来自外部授权，境内运营主体在产品引进后的本地化临床试验、注册和商业化筹备方面工作更为突出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702152222a72a011e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702152222a72a011e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2546747356","title":"维升药业-B(02561)：选举付山继任董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2546747356","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546747356?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 23:02","pubTimestamp":1751036525,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B 发布公告，Michael Wolff JENSEN先生及Jan Mller MIKKELSEN先生已于股东周年大会结束时退任。董事会进一步宣布，其已建议及选举付山先生继任董事会主席，自股东周年大会结束起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1311318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2546719685","title":"维升药业-B06月27日主力净流出29.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2546719685","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546719685?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 16:15","pubTimestamp":1751012151,"startTime":"0","endTime":"0","summary":"06月27日, 维升药业-B股价跌2.00%，报收46.60元，成交金额250.0万元，换手率0.05%，振幅2.73%，量比1.77。维升药业-B今日主力资金净流出29.5万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.31%，主力资金累计净流出3.9万元；近20日主力资金累计净流入350.6万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627173305a7208de5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627173305a7208de5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2546290689","title":"25家中国内分泌与代谢领域创新药公司获融资！","url":"https://stock-news.laohu8.com/highlight/detail?id=2546290689","media":"创鉴汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546290689?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 17:06","pubTimestamp":1750842372,"startTime":"0","endTime":"0","summary":"内分泌与代谢疾病因患者基数庞大且临床需求持续增长，成为创新药研发的重要方向。据公开数据统计，2025年至今，该领域至少发生25起创新药公司融资事件，已披露融资总额超125亿元。AI、新分子实体创新技术引领大额融资：11家公司获得亿元及以上融资。维升药业：内分泌疾病药物研发公司3月21日，维升药业在港交所IPO，募资约6.72亿港元。珂阑医药：胆固醇代谢创新药研发公司2月21日消息，珂阑医药完成超亿元人民币A+轮融资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625171409a4bd09c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625171409a4bd09c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","06978","BK1574","BK1161"],"gpt_icon":0},{"id":"2544157782","title":"维升药业-B06月19日主力净流出27.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2544157782","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544157782?lang=zh_cn&edition=fundamental","pubTime":"2025-06-19 16:15","pubTimestamp":1750320951,"startTime":"0","endTime":"0","summary":"06月19日, 维升药业-B股价跌3.45%，报收49.00元，成交金额320.1万元，换手率0.06%，振幅5.71%，量比0.46。维升药业-B今日主力资金净流出27.7万元，上一交易日主力净流入28.1万元。该股近5个交易日上涨1.55%，主力资金累计净流入325.2万元；近20日主力资金累计净流入199.9万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619174038a4b25192&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619174038a4b25192&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2544978997","title":"维升药业-B06月18日主力净流入28.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2544978997","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544978997?lang=zh_cn&edition=fundamental","pubTime":"2025-06-18 16:15","pubTimestamp":1750234546,"startTime":"0","endTime":"0","summary":"06月18日, 维升药业-B股价涨2.01%，报收50.75元，成交金额291.7万元，换手率0.05%，振幅3.32%，量比0.42。维升药业-B今日主力资金净流入28.1万元，上一交易日主力净流出73.9万元。该股近5个交易日上涨7.98%，主力资金累计净流入352.9万元；近20日主力资金累计净流入275.0万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618173908a71039ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618173908a71039ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2544685549","title":"维升药业-B06月17日主力净流出73.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2544685549","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544685549?lang=zh_cn&edition=fundamental","pubTime":"2025-06-17 16:15","pubTimestamp":1750148126,"startTime":"0","endTime":"0","summary":"06月17日, 维升药业-B股价跌7.53%，报收49.75元，成交金额942.4万元，换手率0.16%，振幅7.99%，量比1.60。维升药业-B今日主力资金净流出73.9万元，上一交易日主力净流入100.7万元。该股近5个交易日上涨3.22%，主力资金累计净流入324.8万元；近20日主力资金累计净流入299.8万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617172843a4adfcbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617172843a4adfcbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2543416623","title":"港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实 那韦培肽新药申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2543416623","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543416623?lang=zh_cn&edition=fundamental","pubTime":"2025-06-16 15:14","pubTimestamp":1750058044,"startTime":"0","endTime":"0","summary":"消息面上，6月9日，维升药业与药明生物宣布，维升药业核心产品隆培促生长素商业化批次的技术转移项目正式落地成都，双方还将在该基地合作建设国内首条双腔冻干制剂生产线，这一创新型药物制剂生产技术能极大地提升药物稳定性及临床使用便捷性。据悉，2023年12月，维升药业与药明生物已就隆培促生长素的技术转移首次达成战略合作。维升药业拥有那韦培肽在大中华区的独家开发、生产和商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1305615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2543681110","title":"医药生物IPO“港漂”热潮：三大热门创新药成焦点，恒瑞医药4个月便实现A+H","url":"https://stock-news.laohu8.com/highlight/detail?id=2543681110","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543681110?lang=zh_cn&edition=fundamental","pubTime":"2025-06-13 19:50","pubTimestamp":1749815428,"startTime":"0","endTime":"0","summary":"部分企业“弃A转港”，或为这波港股医药生物IPO热潮添一把火。排队IPO企业方面，截至今年5月31日，港股医药生物IPO申报企业共有20家。医药生物企业扎堆赴港IPO，或与A股IPO审核趋严有关。未盈利医药生物企业扎堆赴港IPO，与港交所创新性推出的18A上市规则有关。例如，恒瑞医药、派格生物、觅瑞等均在招股书中明确提出“出海”计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613195043951b08b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613195043951b08b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561","09606","01276","BK1191","BK1574","06978"],"gpt_icon":1},{"id":"2542511170","title":"维升药业的独立性与生长激素困局","url":"https://stock-news.laohu8.com/highlight/detail?id=2542511170","media":"市值观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542511170?lang=zh_cn&edition=fundamental","pubTime":"2025-06-12 20:02","pubTimestamp":1749729766,"startTime":"0","endTime":"0","summary":"目前，维升药业旗下最重磅产品为隆培促生长素，已完成三期临床，其上市许可申请已于2024年3月获国家药监局受理，预计在2025年将获准上市。这足见维升药业上市的紧迫性。2023年12月，维升药业与药明生物签订协议，后者作为接收点参与大股东技术转移，最终完成隆培促生长素药物原液的本地商业化供应，预计于2028年实现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612202416a4a52a9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612202416a4a52a9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","HSTECH","BK1161","HSCEI"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":75,"code":"91000000","status":"200"}]}}